Revenue Growth Driven by Organic Demand
Stryker grew Q1 2026 revenue to $6.02B, up $154M or 2.6% year-over-year from $5.87B in Q1 2025, indicating continued demand across its medical device portfolio despite a modest pace of top-line expansion.
STRYKER CORP is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: Stryker delivered a strong Q1 2026 with revenue of $6.02B (+2.6% YoY), net income surging 13.9% to $745M, and operating cash flow more than doubling to $581M, reflecting solid operational leverage and disciplined cost management.
Drawn from management commentary in the Q1 2026 10-Q:
Stryker grew Q1 2026 revenue to $6.02B, up $154M or 2.6% year-over-year from $5.87B in Q1 2025, indicating continued demand across its medical device portfolio despite a modest pace of top-line expansion.
Operating income rose 11.8% YoY to $936M while SG&A expenses declined 0.8% to $2.28B, demonstrating that Stryker is generating more profit per dollar of revenue and improving operational efficiency. Operating margin expanded approximately 130 basis points to 15.5%.
Net income grew 13.9% to $745M and diluted EPS increased 14.2% to $1.93 from $1.69, significantly outpacing the 2.6% revenue growth rate and signaling strong bottom-line leverage from cost controls and potentially lower interest or tax expenses.
Revenue
$6.02B
++2.63% YoY
EPS (Basic)
$1.95
++14.04% YoY
Gross Margin
63.3%
-0.54% YoY
Operating Income
$936M
++11.83% YoY
Add SYK to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.